Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada...
and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 09, 2023 7:30am
New Press Release - Knight Therapeutics Reports Third Quarter 2023 Results
- Achieved Record Nine-month Revenues and Adjusted EBITDA MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended...
read article.
(14)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Nov 09, 2023 4:30am
Buybacks
During the past three months, GUD has bought back around 2.4 million shares. Relative to outstanding shares, this is the highest pace for buybacks we've had. If my numbers are correct:
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 02, 2023 7:30am
New Press Release - Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Following the release, Knight...
read article.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Oct 29, 2023 3:23pm
RE:Jeff Martens
If I were to guess - and only a guess ... There is a very high level of expectation from Management. There is nowhere to hide and you must always be at the top of your game. You are either
...more
(14)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Oct 27, 2023 10:28am
Jeff Martens
As we discussed earlier, mr. Martens was absent from the previous earnings call. Sure enough, according to LinkedIn, his time at Knight ended in June 2023. Whatever happened there? A quiet exit for
...more
(1)
•••
cheching
X
View Profile
View Bullboard History
Post by
cheching
on Oct 16, 2023 9:15pm
Minjuvi
Good News for Brasil, this new drug is promising in the way that it seem to bring diverse use for multiple diseases. On the Incyte website you can also see that the treatment is submited to
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 16, 2023 7:30am
New Press Release - Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market...
read article.
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Oct 16, 2023 5:11am
Weight loss drugs
If novo nordisk , & Eli Lilly & other weight loss drugs prove safe & healthy long term, do these companies have a network in South America ? Do u think our South American distro network
...more
(1503)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Post by
Possibleidiot01
on Oct 14, 2023 1:54pm
5i Research
Review of Knight Therapeutics Sep 21, 2023 The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has
...more
(0)
•••
Stockoman1
X
View Profile
View Bullboard History
Comment by
Stockoman1
on Oct 14, 2023 6:20am
RE:RE:57.08 % shares held In tight hands- sharecount shrinks
Longrun said " I am looking forward to meaningful updates from Management over the coming quarters about profitability! " AMEN !
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Oct 13, 2023 9:44am
Larry fink bullish on healthcare and living longer
Discussing great opportunities in Health care innovation and growth opportunities in Mexico , amongst others - & Great for companies in this area - on CNBC
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 10, 2023 4:45pm
New Press Release - Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA...
read article.
(188)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Oct 08, 2023 11:15am
RE:57.08 % shares held In tight hands- sharecount shrinks
It's always nicer to be in business with "owners" of the company compared to fair-weather "renters". Ultimately though, the return profile based on the capital invested is too
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Oct 06, 2023 7:54pm
57.08 % shares held In tight hands- sharecount shrinks
14.24 held by institutions 42.84% held by insiders 57.08 % shares held also, unsure if these numbers include the buybacks/cancellations, which would just increase their
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test